Key Developments: Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

4,720JPY
26 Dec 2014
Price Change (% chg)

¥6 (+0.12%)
Prev Close
¥4,715
Open
¥4,717
Day's High
¥4,736
Day's Low
¥4,704
Volume
422,700
Avg. Vol
1,815,370
52-wk High
¥5,039
52-wk Low
¥3,694

Search Stocks

Latest Key Developments (Source: Significant Developments)

Eisai Co Ltd Phase III trial shows lenvatinib meets primary endpoint of progression free survival benefit in treatment of redioiodine-refractory differentiated thyroid cancer
Sunday, 2 Feb 2014 10:30pm EST 

Eisai Co Ltd:Says the Phase III SELECT trial of lenvatinib, an investigational selective tyrosine kinase inhibitor with a novel binding mode, the first-in-class of its kind, met its primary endpoint.Says compared to placebo, lenvatinib showed a statistically improvement in progression free survival in patients with radioiodine-refractory differentiated thyroid cancer.  Full Article

Eisai Co Ltd announces result of early-retirement program
Sunday, 2 Feb 2014 10:30pm EST 

Eisai Co Ltd:Says 396 employees have taken up the offer of the early-retirement program announced on Nov. 29, 2013.Says effective date of retirement is Mar. 31.Says a premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.  Full Article

European Commission grants orphan drug status to Eisai Co Ltd's amatuximab for treatment of malignant mesothelioma
Tuesday, 21 Jan 2014 07:01pm EST 

Eisai Co Ltd:Says the investigational monoclonal antibody amatuximab (development code: MORAb-009), has been granted orphan drug designation (ODD) for the treatment of malignant mesothelioma by the European Commission.Says Malignant mesothelioma is a rare form of cancer that affects an estimated in 50,000 (0.2/10,000) people per year in Europe.Says studies have shown highest incidence in the UK and Ireland and lowest in Eastern Europe.Says this aggressive form of lung cancer is caused by asbestos exposure and despite a dramatic decrease in asbestos use since the mid-70s its incidence is expected to increase.Says amatuximab has high affinity and specificity for mesothelin, a protein which is overexpressed in people with malignant mesothelioma.Says amatuximab was discovered and developed through Morphotek, a subsidiary wholly owned by Eisai.  Full Article

Eisai Co Ltd announces new partnership with Esteve to promote anti-epilepsy drug Zonegran (Zonisamide) in Spain
Monday, 9 Dec 2013 07:02pm EST 

Eisai Co Ltd:Says that it has selected Esteve, a Spanish pharmaceutical company with a comprehensive neurology franchise, to become its epilepsy partner in Spain to promote Zonegran (zonisamide).Says Zonisamide, an anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AED, is indicated as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;.Says and as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents and children aged six years and above.  Full Article

Eisai Co Ltd to offer early-retirement program
Friday, 29 Nov 2013 03:00am EST 

Eisai Co Ltd:Says it will offer early-retirement program to employees who is above 45 years old and have been working for the company for above five years as of Mar.31, 2014.Says the program will be offered from Jan.14, 2014 to Jan.24, 2014.Says the employees who took the offer will retire on Mar.31, 2014.  Full Article

Eisai Co Ltd to sell Misato plant business
Friday, 29 Nov 2013 03:00am EST 

Eisai Co Ltd:Says it will sell its Misato plant business to Bushu Pharmaceuticals Ltd.Says the transaction will be completed on Mar.31, 2014.Says the Misato plant produces tablets, capsule and injection.  Full Article

Eisai Co Ltd Announces Partnership With Newbridge to Market Breast Cancer Treatment Halaven (Eribulin) Across Middle East
Sunday, 17 Nov 2013 07:02pm EST 

Eisai Co Ltd announced that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for these treatments.  Full Article

US FDA Approves US Supply Of Epilepsy Drug Zonegran (zonisamide) From Eisai Co Ltd's EMEA Knowledge Centre
Monday, 14 Oct 2013 07:02pm EDT 

Eisai Co Ltd announced that the US Food and Drug Administration (FDA) has approved the US supply of the epilepsy drug Zonegran (zonisamide) from its EMEA (Europe, Middle East, Africa, Russia and Oceania) Knowledge Centre based in Hatfield, UK. The Hatfield site will manufacture and package three different strengths of Zonegran tablet for export to the US. The FDA supply approval for zonisamide follows the approval for the US supply of another Eisai epilepsy drug, Fycompa (perampanel), on 11 September 2013. The manufacturing facility at Hatfield, which also includes Eisai's EMEA sales and marketing and R&D operations, is increasing in significance to the Company's worldwide business as it continues becomes a global supply centre for products such as zonisamide and perampanel.  Full Article

Eisai Co Ltd's Subsidiary Ties Up with Polish Firm to Create New Cancer Drugs - Asahi Shimbun
Wednesday, 18 Sep 2013 08:00pm EDT 

Asahi Shimbun reported that Eisai Co Ltd's United States-based research subsidiary has entered into an agreement with Poland's Selvita S.A., a drug research company in Eastern Europe, to create new cancer drugs.  Full Article

Eisai Co Ltd to Sell Holdings in Subsidiary to Lawson, Inc.
Friday, 19 Jul 2013 02:00am EDT 

Eisai Co Ltd announced that it has decided to divest its holdings of a 70% stake (3,500 shares) in a subsidiary, Eisai Seikaken Co., Ltd. to Lawson, Inc., effective August 30, 2013. The transaction price is not disclosed. After this, Eisai Co Ltd will hold no stake in Eisai Seikaken Co., Ltd.  Full Article

BRIEF-Oncodesign enters into services agreement with Eisai

* Says it has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

Search Stocks